BeOne Medicines (BEIGF) Interest Expenses (2015 - 2026)
BeOne Medicines' (BEIGF) quarterly Interest Expenses came in at $39.7 million in Q2 2026, up 397.05% year-over-year from $8.0 million in Q2 2025, and up 20.83% quarter-over-quarter from $32.9 million in Q1 2026.
Powered by 
Analysis
BeOne Medicines (BEIGF) Interest Expenses (2015 - 2026) Analysis & Trends
BeOne Medicines (BEIGF) has reported Interest Expenses for 4 consecutive years, with $39.7 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Interest Expenses rose 397.05% year-over-year to $39.7 million in Q2 2026; TTM through Jun 2026 was $87.6 million, a 468.17% increase from a year earlier, with the FY2025 full-year figure at $58.2 million, up 167.07% from the prior year.
- Interest Expenses was $39.7 million for Q2 2026 at BeOne Medicines, up from $32.9 million in the prior quarter.
- Over five years, Interest Expenses peaked at $39.7 million in Q2 2026 and troughed at $7.0 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.43 Bn | 625.67 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 442.46 Bn | 435.89 Bn | 12.70 Bn | - |
| 3 | Merck | 366.77 Bn | 359.63 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.59 Bn | 258.90 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 2.90 Mn |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 39.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 39.74 Mn |
| Mar 31, 2026 | 32.89 Mn |
| Jun 30, 2025 | 8.00 Mn |
| Mar 31, 2025 | 7.00 Mn |
| Sep 30, 2016 | 284,000.00 |
| Jun 30, 2016 | 141,000.00 |
| Mar 31, 2016 | 204,000.00 |
| Sep 30, 2015 | 300,000.00 |
| Jun 30, 2015 | 273,000.00 |
| Mar 31, 2015 | 267,000.00 |